Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics of the patients with NMOSD and CIS/RRMS as well as of healthy controls included in this study

From: Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis

Serum (NGS)
  NMOSD (n = 20) CIS/RRMS (n = 20; 16/4) Healthy controls (n = 20) p valuea
 Females/males (% female) 18/2 (90) 13/7 (65) 13/7 (65) 0.13
 Median age, y (range) 49.5 (18–75) 33 (20–41) 32 (21–42) 0.004
 Median EDSS (range) 4 (1–9) 1.25 (0–2.5)
 Immunotherapy (number) AZA (7) AZA + S (2) MTX + Quensyl (1) GLAT (1) RTX (6) MMF (1) None (2) Interferon-beta (1) none (19)
Whole blood (NGS)
  NMOSD (n = 11) CIS/RRMS (n = 60; 50/10)b Healthy controls (n = 43)c p value
 Females/males (% female) 10/1 (91) 38/22 (63) 23/20 (53.5) 0.07
 Median age, y (range) 34 (21–75) 31.5 (19–50) 60 (21–83) 0.0003
 Median EDSS (range) 4 (1–9) 1.5 (0–3.5)d
 Immunotherapy AZA (3) AZA + S (1) MTX + Quensyl (1) GLAT (1) RTX (4) None (1) Interferon-beta (1) None (59)
qRT-PCR validation study
  NMOSD (n = 19) CIS/RRMS (n = 19; 15/4) p value
 Females/males (% female) 17/2 (85) 17/2 (85) 1.0
 Median age, y (range) 50 (21–75) 41 (23–51) 0.1
 Median EDSS (range) 3.75 (1–9) 2 (0–3.5)
 Immunotherapy (number) AZA (7) AZA + S (2) MTX + Quensyl (1) GLAT (1) RTX (5) MMF (1) None (2) GLAT (2) Interferon-beta (4) None (13)
  1. NGS next-generation sequencing, y years, EDSS expanded disability status scale, AZA azathioprine, AZA + S azathioprine and corticosteroids, MTX methotrexate, GLAT glatiramer acetate, RTX rituximab, MMF mycophenolate mofetil, CIS clinically isolated syndrome, RRMS relapsing-remitting multiple sclerosis, NMOSD neuromyelitis optica spectrum disorder
  2. aGender distribution was assessed by 2 × 3 or 2 × 2 Fisher exact test and age differences by Kruskal-Wallis or Mann-Whitney tests
  3. bForty-four of the 60 patients with CIS/RRMS included in this work were recruited in the present study and 16 miRNA expression profiles were from a previous work [25]
  4. cBlood miRNA profiles from the 43 healthy controls were obtained in two previous projects (n = 21 from Keller et al. [25] and n = 22 from Leidinger et al. [29])
  5. dEDSS values were only available for the 44 patients recruited in the present study